Arosio E, Pancera P, Sheiban I, Priante F, Ribul M, De Marchi S, Tonni S, Lechi A
Clinica Medica, Università di Verona, Italy.
J Hum Hypertens. 1996 Mar;10(3):171-6.
We evaluated the modifications induced by chronic treatment with an alpha 1-adrenolytic hybrid drug, urapidil, on the hemodynamic parameters in peripheral artery and left ventricle diastolic function. Fifteen mild to moderate essential hypertensive patients (13 men, 2 women; mean age 42 years, range 32-54 years) received urapidil (60 mg b.i.d.) for 6 months. Peripheral hemodynamic and cardiac parameters were evaluated by duplex scanner, coupled with a plethysmographic method, basally (T0) and after 6 weeks' (T1) and 6 months' treatment (T2). Mean blood pressure (BP) showed a reduction after 6 weeks of -9.07 mm Hg (confidence intervals [CI] 95%: -9.21; -8.92; P < 0.01), which was maintained after 6 months (-8.21 mm Hg, CI 95%: -8.97; -7.43; P < 0.01), while no significant change was seen in heart rate. Compliance showed highly significant changes after both 6 weeks (+1.073 dyn-1.cm4.10(-7), 95% CI: +0.965; +1.181, P < 0.001) and 6 months (+0.933 dyn-1.cm4. 10(-7), 95% CI: +0.903; +0.963, P < 0.001), as well as characteristic impedance (T1:-16.689 dyn.s.cm-5/10(2), 95% CI: -16.914; -16.463 P < 0.001; T2: -15.98 dyn.s.cm-5. 10(2), 95% CI: -18.186; -13.784; P < 0.001) and forearm resistances (T1: -26.153 mm Hg.ml-1.s, 95% CI: -34.553; -17.753, P < 0.01; T2: -43.587 mm Hg.ml-1.s, 95% CI: -52.711; -34.464, P < 0.01). Similarly, we have recorded a similar change in left ventricular end-diastolic posterior wall thickness (T1: -1.067 mm, 95% CI: -1.099; -1.035, P < 0.01; T2: -2.866 mm, 95% CI: -3.044; -2.688, P < 0.01), end-diastolic interventricular septum thickness (T1: -0.921 mm, 95% CI: -1.511; -0.289, P < 0.05; T2: -2.711 mm, 95% CI: -3.211; -2.199, P < 0.01), end-diastolic volume (T1: +6.4 ml, 95% CI: +6.343; +6.456, P < 0.01; T2: +19.867 ml, 95% CI: +18.564; +21.170, P < 0.01), and mass/volume index (T1: -0.11, 95% CI: -0.118; -0.101, P < 0.01; T2: -0.218, 95% CI: -0.221; -0.217, P < 0.01). Changes in arterial compliance have shown a statistically significant correlation with changes in mass/volume index (r = -0.468; P < 0.03), end diastolic volume (r = 0.501; P < 0.02), as well as left ventricle rapid filling phase (r = 0.426; P < 0.05) and left ventricle end diastolic posterior wall thickness (r = -0.478, P < 0.03). Our results suggest that the antihypertensive efficacy of urapidil coupled with the restoration of the dumping function of the large arteries, and the reduced activation of reflex sympathetic activation, may play a considerable role among the mechanisms allowing the regression of the functional modifications affecting the left ventricular diastole.
我们评估了α1-肾上腺素能阻断混合药物乌拉地尔长期治疗对外周动脉血流动力学参数和左心室舒张功能的影响。15例轻度至中度原发性高血压患者(13例男性,2例女性;平均年龄42岁,范围32 - 54岁)接受乌拉地尔(60 mg,每日两次)治疗6个月。采用双功扫描仪结合体积描记法,在基线(T0)、治疗6周后(T1)和6个月后(T2)评估外周血流动力学和心脏参数。平均血压(BP)在6周后降低了9.07 mmHg(95%置信区间[CI]:-9.21;-8.92;P < 0.01),6个月后维持在-8.21 mmHg(95% CI:-8.97;-7.43;P < 0.01),而心率无显著变化。顺应性在6周后(+1.073 dyn-1.cm4.10(-7),95% CI:+0.965;+1.181,P < 0.001)和6个月后(+0.933 dyn-1.cm4.10(-7),95% CI:+0.903;+0.963,P < 0.001)均有高度显著变化,特征阻抗(T1:-16.689 dyn.s.cm-5/10(2),95% CI:-16.914;-16.463,P < 0.001;T2:-15.98 dyn.s.cm-5.10(2),95% CI:-18.186;-13.784;P < 0.001)和前臂阻力(T1:-26.153 mmHg.ml-1.s,95% CI:-34.553;-17.753,P < 0.01;T2:-43.587 mmHg.ml-1.s,95% CI:-52.711;-34.464,P < 0.01)也有类似变化。同样,我们记录到左心室舒张末期后壁厚度(T1:-1.067 mm,95% CI:-1.099;-1.035,P < 0.01;T2:-2.866 mm,95% CI:-3.044;-2.688,P < 0.01)、舒张末期室间隔厚度(T1:-0.921 mm,95% CI:-1.511;-0.289,P < 0.05;T2:-2.711 mm,95% CI:-3.211;-2.199,P < 0.01)、舒张末期容积(T1:+6.4 ml,95% CI:+6.343;+6.456,P < 0.01;T2:+19.867 ml,95% CI:+18.564;+21.170,P < 0.01)以及质量/容积指数(T1:-0.11,95% CI:-0.118;-0.101,P < 0.01;T2:-0.218,95% CI:-0.221;-0.217,P < 0.01)均有类似变化。动脉顺应性的变化与质量/容积指数的变化(r = -0.468;P < 0.03)、舒张末期容积的变化(r = 0.501;P < 0.02)、左心室快速充盈期的变化(r = 0.426;P < 0.05)以及左心室舒张末期后壁厚度的变化(r = -0.478,P < 0.03)均存在显著的统计学相关性。我们的结果表明,乌拉地尔的降压效果,以及大动脉缓冲功能的恢复和反射性交感神经激活的减少,可能在使影响左心室舒张的功能改变消退的机制中起重要作用。